Skip to main content
. 2022 Dec 6;14(12):2728. doi: 10.3390/pharmaceutics14122728

Figure 8.

Figure 8

The figure represents different applications of PLGA. (A) Optical photographs taken of the entire mouse after 2, 24, 48, 72, 96, 168, and 240 h after subcutaneous injection of 500 µg of fluorescent PLGA-NPs in the right flank in a syngeneic tumor-bearing mouse. (B) Analyzing the PLGA-NPs’ biodistribution in BALB/c mice. This data is shown as the mean fluorescence (NET/Area) ±SD from 5 different mice at each time point. (C) Images of two syngeneic J744a-carrying mice. 1 tumor located in the right thigh, obtained 24 h post-injection (p.i.) of either native PLGA-NPs (left) or VEGF-PLGA-NPs (right). (D) TPLGA NP biodistribution in vivo. 24 h post-injection ex vivo fluorescent pictures of key organs and 4T1 tumors were observed. Red circles indicate tumor locations. Fluorescence intensity decreases from red to blue. (E) Tumor and major organ DOX content was determined 24 h after tail-vein injection with free DOX and DOX-loaded NPs. Mean ± SD (n = 3) was used. * p < 0.05, ** p < 0.01, and *** p < 0.001. Figure (A–C) is reproduced from [101] and Figure (D,E) are adapted from [96] with copyright permission.